Kodiak Sciences (NASDAQ:KOD) Sees Strong Trading Volume After Analyst Upgrade

Key Points

• Trading volume increased 36% after Lifesci Capital raised Kodiak Sciences’ price target from $85 to $145 and maintained an “outperform” rating. About 1.41 million shares traded, while the stock was recently around $88.
• Analyst sentiment is broadly positive: six analysts rate KOD a “Buy,” with a consensus “Moderate Buy” rating and an average price target of $90.86, although ratings range from “Strong Sell” to “Neutral.”
• Risks remain significant: Kodiak is loss-making, recently missed quarterly EPS expectations, and still faces regulatory and commercialization hurdles; elevated volatility and heavy put-option activity suggest some investors are hedging against a pullback.

Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) saw an uptick in trading volume on Tuesday after Lifesci Capital raised their price target on the stock from $85.00 to $145.00. Lifesci Capital currently has an outperform rating on the stock. Approximately 1,414,667 shares were traded during mid-day trading, an increase of 36% from the previous session's volume of 1,043,171 shares. The stock last traded at $88.0720 and had previously closed at $89.92.

KOD has been the subject of several other research reports. Wall Street Zen cut Kodiak Sciences from a "sell" rating to a "strong sell" rating in a research report on Saturday. UBS Group upped their price target on Kodiak Sciences from $80.00 to $120.00 and gave the stock a "buy" rating in a research note on Monday. JPMorgan Chase & Co. lifted their price objective on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an "overweight" rating in a research report on Monday, August 3rd. HC Wainwright raised their target price on shares of Kodiak Sciences from $58.00 to $96.00 and gave the company a "buy" rating in a research note on Monday. Finally, The Goldman Sachs Group assumed coverage on shares of Kodiak Sciences in a research note on Thursday, September 24th. They issued a "neutral" rating and a $36.00 price target on the stock. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kodiak Sciences has a consensus rating of "Moderate Buy" and a consensus target price of $90.86.

Key Stories Impacting Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Major Phase 3 clinical success: Zenkuda and tabirafusp-ted (formerly KSI-501) both met their primary endpoints in the DAYBREAK trial. The treatments reportedly delivered vision outcomes comparable to Eylea, while Kodiak highlighted their potential for longer-lasting disease control. Why Kodiak Sciences Skyrocketed Today
• Positive Sentiment: Regulatory path is advancing: Kodiak plans to seek regulatory approval for Zenkuda following the successful trial, bringing a potentially commercial retinal medicine closer to market. The global retinal-drug market is expected to exceed $32 billion by the end of the decade. Kodiak Sciences Stock Pops After Eye-Disease Drugs Pass Key Trial
• Positive Sentiment: Analyst sentiment strengthened: UBS raised its price target from $80 to $120 and assigned a “buy” rating. Lifesci Capital raised its target from $85 to $145 and rated the shares “outperform,” while HC Wainwright increased its target from $58 to $96 and maintained a “buy” rating.
• Neutral Sentiment: Investor attention and volatility are elevated: KOD reached a new 12-month high and has risen substantially over the past year, reflecting a sharp reassessment of its prospects. The move also leaves the stock vulnerable to profit-taking and large price swings. Kodiak Sciences Shares Hit 52-Week High After Positive Phase 3 Trial
• Negative Sentiment: Bearish hedging appeared in the options market: Traders purchased 21,273 put options, roughly 1,361% above typical daily volume. This may signal hedging or speculation that the stock’s rally could reverse.
• Negative Sentiment: Execution and valuation risks remain: Kodiak still must complete regulatory filings, obtain approval and successfully commercialize the products. The company remains loss-making, and the stock’s elevated valuation and dependence on a small number of late-stage assets increase downside risk if follow-up data or regulators disappoint.

Institutional Trading of Kodiak Sciences

Several institutional investors and hedge funds have recently made changes to their positions in KOD. V Square Quantitative Management LLC purchased a new position in Kodiak Sciences in the first quarter valued at about $26,000. Westfuller Advisors LLC purchased a new position in shares of Kodiak Sciences in the 1st quarter valued at approximately $26,000. EverSource Wealth Advisors LLC boosted its stake in Kodiak Sciences by 1,221.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company's stock worth $28,000 after purchasing an additional 916 shares in the last quarter. KBC Group NV acquired a new stake in Kodiak Sciences in the 1st quarter worth approximately $39,000. Finally, E Fund Management Co. Ltd. purchased a new stake in Kodiak Sciences during the 2nd quarter worth approximately $228,000. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences Trading Down 3.9%

The company has a market cap of $5.43 billion, a PE ratio of -20.63 and a beta of 2.18. The firm's 50-day simple moving average is $39.29 and its two-hundred day simple moving average is $37.80.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.96) by ($0.09). As a group, analysts predict that Kodiak Sciences Inc. will post -3.89 EPS for the current year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc NASDAQ: KOD is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company's research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.